RADIATE: more treatment options for patients with an inadequate response to tumor necrosis factor antagonists

被引：7

作者：

Choy, Ernest ^{[1
]}

机构：

[1] Kings Coll London, Acad Dept Rheumatol, Weston Educ Ctr, Sir Alfred Baring Garrod Clin Trials Unit, London SE5 9RJ, England

来源：

NATURE CLINICAL PRACTICE RHEUMATOLOGY | 2009年 / 5卷 / 02期

关键词：

interleukin-6; rheumatoid arthritis; tocilizumab; treatment; INTERLEUKIN-6 RECEPTOR INHIBITION; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; TOCILIZUMAB; MULTICENTER; OUTCOMES; TRIAL; AGENT;

D O I：

10.1038/ncprheum0984

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Over the last decade, the use of tumor necrosis factor (TNF) inhibitors has improved the prognosis of patients with rheumatoid arthritis. Although these agents are more efficacious than traditional DMARDs, a substantial proportion of patients discontinue anti-TNF therapy because of adverse effects or lack of efficacy. Therapeutic options for these patients include dose increases, switching to an alternative TNF antagonist, or switching to a biologic of a different class, such as rituximab or abatacept. The recently published results of the RADIATE study by Emery et al. suggest that the interleukin-6 inhibitor tocilizumab is a safe and effective alternative for patients who fail to respond to anti-TNF therapy. Randomized controlled trials and the study of biomarkers are needed to help clinicians select the most suitable of these options for their patients.

引用

页码：66 / 67

页数：2

共 9 条

[1] Advances in targeted therapies X [J].

Breedveld, F. C. ;

Kalden, J. R. ;

Smolen, J. S. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 :1-1

[2] Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks [J].

Cohen, Stanley B. ;

Emery, Paul ;

Greenwald, Maria W. ;

Dougados, Maxime ;

Furie, Richard A. ;

Genovese, Mark C. ;

Keystone, Edward C. ;

Loveless, James E. ;

Burmester, Gerd-Ruediger ;

Cravets, Matthew W. ;

Hessey, Eva W. ;

Shaw, Timothy ;

Totoritis, Mark C. .

ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2793-2806

[3] IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial [J].

Emery, P. ;

Keystone, E. ;

Tony, H. P. ;

Cantagrel, A. ;

van Vollenhoven, R. ;

Sanchez, A. ;

Alecock, E. ;

Lee, J. ;

Kremer, J. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (11) :1516-1523

[4] B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents [J].

Finckh, Axel ;

Ciurea, Adrian ;

Brulhart, Laure ;

Kyburz, Diego ;

Moeller, Burkhard ;

Dehler, Silvia ;

Revaz, Sylvie ;

Dudler, Jean ;

Gabay, Cem .

ARTHRITIS AND RHEUMATISM, 2007, 56 (05) :1417-1423

[5] Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study [J].

Genovese, Mark C. ;

McKay, James D. ;

Nasonov, Evgeny L. ;

Mysler, Eduardo F. ;

da Silva, Nilzio A. ;

Alecock, Emma ;

Woodworth, Thasia ;

Gomez-Rein, Juan J. .

ARTHRITIS AND RHEUMATISM, 2008, 58 (10) :2968-2980

[6] Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition [J].

Genovese, MC ;

Becker, J ;

Schiff, M ;

Luggen, M ;

Sherrer, Y ;

Kremer, J ;

Birbara, C ;

Box, J ;

Natarajan, K ;

Nuamah, I ;

Li, T ;

Aranda, R ;

Hagerty, DT ;

Dougados, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (11) :1114-1123

[7] Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis -: Results from a large UK national cohort study [J].

Hyrich, Kimme L. ;

Lunt, Mark ;

Watson, Kath D. ;

Symmons, Deborah P. M. ;

Silman, Alan J. .

ARTHRITIS AND RHEUMATISM, 2007, 56 (01) :13-20

[8] Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab [J].

Nishimoto, Norihiro ;

Hashimoto, Jun ;

Miyasaka, Nobuyuki ;

Yamamoto, Kazuhiko ;

Kawai, Shinichi ;

Takeuchi, Tsutomu ;

Murata, Norikazu ;

van der Heijde, Desiree ;

Kishimoto, Tadamitsu .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (09) :1162-1167

[9] Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial [J].

Smolen, Josef S. ;

Beaulieu, Andre ;

Rubbert-Roth, Andrea ;

Ramos-Remus, Cesar ;

Rovensky, Josef ;

Alecock, Emma ;

Woodworth, Thasia ;

Alten, Rieke .

LANCET, 2008, 371 (9617) :987-997

← 1 →